Anti-PCSK9 (3D2)

Anti-PCSK9 [3D2], Recombinant, IgG1 kappa, Human
SKU
ABAAb02937-10.3
Packaging Unit
200 μg
Manufacturer
Absolute Antibody

Availability: loading...
Price is loading...
CloneID: 3D2

Heavy Chain modification: Fc Silent™

Antigen Long Description: The original antibody was isolated from an scFv phage display library generated from blood, bone marrow, and cord blood samples from healthy donors by panning against recombinant PCSK9.

Origin Pub PMID: 33416098

Buffer Composition: PBS with 0.02% Proclin 300.

Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7

Uniprot Accession No.: Q8NBP7

Specificity Statement: This antibody binds PCSK9 and blocks the PCSK9-LDLR interaction in a dose-dependent manner with an IC50 of 2.25±1.23 nM (PMID: 33416098). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.

Application Notes (Clone): Indirect binding ELISA were performed to assess the specificity of this antibody against PCSK9. Biolayer interferometry analysis suggested that IgG1 version of this antibody had a binding affinity of 1.96±1.56X10−10 M towards PCSK9. In vitro, the PCSK9/low-density lipoprotein receptor (LDLR) pathway of Hep-G2 cells was inhibited by 3D2 treatment, thereby increasing LDL uptake in these cells. In addition, combination treatment with 3D2 and statin was more effective at increasing LDLR levels than treatment with 3D2 or statin alone. Furthermore, in mice treatment with this antibody resulted in a 3-fold increase in hepatic LDLR levels, and lowered total serum cholesterol by up to 61.5% in vivo (PMID: 33416098).
More Information
SKU ABAAb02937-10.3
Manufacturer Absolute Antibody
Manufacturer SKU Ab02937-10.3
Package Unit 200 μg
Quantity Unit STK
Reactivity Human
Clonality Recombinant
Application ELISA, Blocking, Functional Assay, BLI Binding Assay, Inhibition
Isotype IgG1 kappa
Host Human
Product information (PDF)
×
MSDS (PDF) Download